APO010

DRUG2 trials

Sponsors

Valerio Therapeutics, Allarity Therapeutics

Conditions

CancerRelapsed/Refractory Multiple Myeloma

Phase 1

A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors

CompletedNCT00437736

Valerio TherapeuticsCancer

Start: 2007-02-28End: 2009-05-31Updated: 2015-09-17

Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP

TerminatedNCT03196947

Allarity TherapeuticsRelapsed/Refractory Multiple Myeloma

Start: 2017-06-13End: 2020-01-16Updated: 2020-01-30